Accuray installs 200th CyberKnife robotic radiosurgery system

Thursday 3rd June 2010

Accuray Incorporated, a global leader in the field of radiosurgery, have announced the installation of the 200th CyberKnife robotic radiosurgery system as continued evidence of its acceptance as the world's leading device for radiosurgery.

The milestone system was installed at Mount Vernon Cancer Centre in the United Kingdom, the first hospital operated by the National Health Service (NHS) in the UK to acquire the CyberKnife device.

Accuray has made significant investment in the clinical and technology areas needed to support its high rate of growth. The total number of publications supporting CyberKnife System use increased from just over 50 publications in the beginning of 2002 to more than 430 publications currently.

And as clinical evidence mounts, access to CyberKnife radiosurgery continues to accelerate. From the launch of the first commercially available CyberKnife System in 2003, CyberKnife System installations have grown to now 200 worldwide, with over 50 percent of these installed since January 2007.

Also more than 90,000 patients have been treated with over two-thirds of the treatments completed during this same period. Today extracranial use, including prostate and lung, is the fastest growing area for the device, making up more than 50 percent of all cases.

"We celebrate this milestone installation as another step toward expanded patient access to the clinical benefits of the CyberKnife System and as confirmation of the growing market for radiosurgery," said Euan S Thomson, PhD, president and CEO of Accuray.

"Between CyberKnife installations and associated service agreements, the cumulative investment in radiosurgery with the Accuray CyberKnife System totals nearly one billion US dollars."

Accuray continues to increase support of clinical studies of the CyberKnife System in full body radiosurgery, also known as stereotactic body radiation therapy (SBRT). Among the 80 papers published on CyberKnife usage since July, 2009, seven papers reported on the rapidly increasing experience in CyberKnife prostate radiosurgery with two reporting erectile function preservation levels that rivaled historical results of other prostate cancer treatments. Additionally, a global, multi-institution study led by MD Anderson Cancer Center in Houston, TX is comparing treatment outcomes of surgery with non-invasive CyberKnife radiosurgery in early-stage operable lung cancer.

"We are very proud to have the first UK NHS installation of Accuray's CyberKnife System and are excited that we will be able to bring the benefits of CyberKnife radiosurgery to the patients we serve," said Professor Peter Hoskin, Radiation Oncologist at Mount Vernon Cancer Center.

"We decided to purchase this device to add additional capability at Mount Vernon Cancer Centre in the field of complex radiation therapy, an area which is growing rapidly. The CyberKnife System will allow us to develop techniques and treatments previously unavailable to our patients."

The CyberKnife System was first cleared by the US Food & Drug Administration (FDA) in 1999 for the treatment of tumors in the head, neck and upper spine. In 2001, clearance was expanded to include tumors anywhere in the body and was first CE Marked in 2002.

Accuracy

Feedback

Have YOUR say.

Name:
Email:
Location:

We welcome all feedback. However, we cannot publish anonymous comments, so please supply your name and location. Your details will not be displayed if you so request. To protect privacy we never publish email addresses.